Back

Prospective evaluation of cardiac function following anti-BCMA CAR-T therapy in multiple myeloma

21 June 2025 (13:40 - 13:50)
Organised by: Logo
Congress Presentation Part of: Risk stratification for cancer therapy-related cardiovascular disease Cancer Biology and Treatment CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Isamu Sunayama

Hyogo College of Medicine, Nishinomiya (Japan)

5 More presentations in this session

Presentation thumbnail
Non-uniform cardiovascular risks of tyrosine kinase inhibitors associated with inhibition of C-terminal Src kinase
Assistant Professor Y. Chan (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
The emerging role of left atrial strain in cardiovascular risk stratification for multiple myeloma patients undergoing carfilzomib therapy
Doctor A. Colomba (Candiolo, IT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular adverse events with cdk4/6 inhibitors:a meta-analysis of randomized controlled trials
Associate Professor C. Dolladille (Caen, FR)
Abstract Slides Video
Presentation thumbnail
Machine learning modelling using cardiac magnetic resonance images to predict cancer therapy related cardiac dysfunction with external validation in HER2+ breast cancer patients
Professor P. Thavendiranathan (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Cardiovascular safety of modern radiotherapy techniques in breast cancer
Mr J. Saldana Garcia (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification for cancer therapy-related cardiovascular disease

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 13:40 CET
You may be interested in
thumbnail
Congress Presentation
Prospective evaluation of cardiac function in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T therapy
thumbnail
Congress Presentation
Cardiovascular complications of chimeric antigen receptor (CAR)-T cell therapy
thumbnail
Congress Presentation
Cardiovascular implications of CAR-T cell therapy: insights from a regional cardio-oncology program

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources